Overview
GH Research is a clinical-stage biopharmaceutical company developing inhaled 5-MeO-DMT (GH001) as a rapid-acting treatment for treatment-resistant depression. Their proprietary inhalation delivery method is designed to produce predictable, short-duration psychedelic experiences.
More in Mental Health Tech
Latest industry news
ReVision Implant Secures €4 Million to Advance Next-Generation Visual Neuroprosthetics
2026-07-25 · Funding
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Advance Neuroscience Therapeutics
2026-07-24 · Funding
Science Corp. Launches Prima BCI Implant in Europe, Bringing Vision Restoration to a New Market
2026-07-23 · Product
First Able-Bodied Individuals Receive Brain-Computer Implants in Landmark Expansion of BCI Eligibility
2026-07-22 · Research
Company details
Category
💙 Mental Health Tech
Location
Dublin, Ireland
Funding
Public · NASDAQ: GHRS
Website
gh.bioListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →